Alerts
Pancreatic Cancer Is Forcing Regulators to Move Faster
EMA has started a phased review of daraxonrasib in pancreatic cancer, while Revolution Medicines says its U.S. rolling NDA is nearing completion. The science is moving into the regulatory fast lane. Access systems are not ready yet.
Ebola Has Passed 2,000 Cases. The Response Is Still Chasing It.
Medicare Is Coming for the Oncology Margin
Ebola May Be Reaching Kisangani. Containment Cannot Stay Provincial.
Pancreatic Cancer’s ADC Moment Will Live or Die by the Biomarker
Moldova Is Taking Vaccines To Roma Communities. Respect Is Part Of Delivery.
KRAS Has a New Contender. It Still Has to Earn Its Place.
Stroke Rehab Cannot Stop at Survival
Disaster Shelters Save Lives. Infection Control Cannot Be Improvised.
China’s Biliary-Cancer Bet Has a Global Access Problem
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.